CDC25C and cancer: Initial in vitro results showed additive and synergistic effects with other cell cycle inhibitors indirectly, or directly in the CDC25-specific inhibition paradigm that proved promising in their anti-proliferative action on various cancer cell lines (Larsson et al., 2009; Ock and Kim, 2021; Zhao et al., 2023).